Obinutuzumab: A new class of anti-CD20 monoclonal antibody

Current Opinion in Oncology

Volumn 26, Issue 5, 2014, Pages 484-491

  Gagez, Anne Laure ^a,b   Cartron, Guillaume ^a,b,c  

^a UNIV MONTPELLIER   (France)

^b Université de Tours   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

antibody dependent cellular cytotoxicity; CD20; glycoengineering; obinutuzumab; type II antibody

Indexed keywords

BENDAMUSTINE; CD16 ANTIGEN; CD20 ANTIBODY; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPITOPE; FC RECEPTOR; LENALIDOMIDE; MONOCLONAL ANTIBODY; OBINUTUZUMAB; PREDNISONE; RITUXIMAB; VENETOCLAX; VINCRISTINE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTIGEN EXPRESSION; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOTOXICITY; DRUG ACTIVITY; DRUG MECHANISM; EFFECTOR CELL; HODGKIN DISEASE; HUMAN; INFUSION RELATED REACTION; LARGE CELL LYMPHOMA; LYMPHOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; ANIMAL; CELL DEATH; DRUG EFFECTS; IMMUNOLOGY; LYMPHOPROLIFERATIVE DISORDERS; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD20; CELL DEATH; HUMANS; LYMPHOPROLIFERATIVE DISORDERS;

EID: 84906092974     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000107     Document Type: Review

References (35)

1. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-1174
2. Gao G, Liang X, Jiang J, et al. A systematic review and meta-Analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma. Acta Oncol 2010; 49: 3-12
3. Schulz H, Bohlius J, Skoetz N, et al. Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Cochrane Database Syst Rev 2007; 4: CD003805
4. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99: 754-758
5. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: Ways to improve rituximab efficacy. Blood 2004; 104: 2635-2642
6. Forero-Terres A, de Vos S, Pohlman BL, et al. Results of phase I study of AME-133 v (LY2469298) an FC-engineering humanized monoclonal anti-CD20 antibody, in FcgRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res 2012; 18: 1395-1403
7. Cazin B, Lepretre S, Coiffier B, et al. Multicentre phase I study with an 8-dose regimen of single agent anti-CD20 monoclonal antibody LFB-R603 in patients with relapsed chronic lymphocytic leukemia (CLL). Blood 2011; 118: 1234-1235
8. Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115: 4393-4402
9. Goede V, Kirsten F, Bushe R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370: 1101-1110
10. Bubien JK, Zhou LJ, Bell PD, et al. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol 1993; 121: 1121-1132
11. Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003; 101: 1045-1052
12. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004; 103: 2738-2743
13. Ivanov A, Beers SA, Walshe CA, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosomemediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009; 119: 2143-2159
14. Alduaij W, Ivanov A, Honeychurch J, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011; 117: 4519-4529
15. Niederfellner G, Lammens A, Mundigl O, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 2011; 118: 358-367
16. Beers SA, French RR, Chan HT, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: Implications for antibody selection. Blood 2010; 115: 5191-5201
17. Koene HR, Kleijer M, Algra J, et al. Fc gammaRIIIa-158 V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997; 90: 1109-1114
18. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940-3947
19. Treon SP, Hansen M, Branagan AR, et al. Polymorphisms in FcgIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. J Clin Oncol 2005; 23: 474-481
20. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26: 1789-1796
21. Bibeau F, Crapez E, Di Fiore F, et al. Association of FcgRIIa and FcgRIIIa polymorphisms with clinical outcome in metastatic colorectal cancer patients (mCRC) treated with cetuximab and irinotecan. J Clin Oncol 2009; 27: 1122-1129
22. Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for FcgRI, Fc gRII, Fc gRIII, and FcRn and design of IgG1 variants with improved binding to the FcgR. J Biol Chem 2001; 276: 6591-6604
23. Shields RL, Lai J, Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcgRIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277: 26733-26740
24. De Romeuf C, Dutertre CA, Le Garff-Tavernier M, et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. Br J Haematol 2008; 140: 635-643
25. Okazaki A, Shoji-Hosaka E, Nakamura K, et al. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and Fc gRIIIa. J Mol Biol 2004; 336: 1239-1249
26. Herter S, Birk MC, Klein C, et al. Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. J Immunol 2014; 192: 2252-2260
27. Golay J, Da Roit F, Bologna L, et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood 2013; 122: 3482-3491
28. Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and of atumumab in vitro and in xenograft models. Mol Cancer Ther 2013; 12: 2031-2042
29. Salles G, Morschhauser F, Lamy T, et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 2012; 119: 5126-5132
30. Cartron G, Lamy T, Morschhauser F, et al. Phase I study of R05072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia. Haematologica 2009; 94: 201-1201
31. Salles GA, Morschhauser F, Solal-Cé ligny P, et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: Results from the phase II GAUGUIN study. J Clin Oncol 2013; 31: 2920-2926
32. Morschhauser FA, Cartron G, Thieblemont C, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantlecell lymphoma: Results from the phase II GAUGUIN study. J Clin Oncol 2013; 31: 2912-2919
33. Cartron C, Morschhauser F, Thieblemont C, et al. Results from a phase II study of obinutuzumab (GA101) monotherapy in relapsed/refractory chronic lymphocuyic leukemia (CLL). Haematologica 2011; 96: 39-139
34. Radford J, Davies A, Cartron G, et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: Results of the GAUDI study (BO21000). Blood 2013; 122: 1137-1143
35. Sehn LH, Goy A, Offner FC, et al. Randomized phase II trial comparing GA101 (obinutuzumab) with rituximab in patients with relapsed CD20+indoindolent B-cell non-Hodgkin lymphoma: Preliminary analysis of the GAUSS study. Blood 2011; 118: 124-1124